Skip to main content Accessibility help
×
Hostname: page-component-76fb5796d-vfjqv Total loading time: 0 Render date: 2024-04-25T12:15:06.412Z Has data issue: false hasContentIssue false

99 - Nimodipine

Published online by Cambridge University Press:  06 October 2020

Stephen D. Silberstein
Affiliation:
Thomas Jefferson University, Philadelphia
Michael J. Marmura
Affiliation:
Thomas Jefferson University, Philadelphia
Hsiangkuo Yuan
Affiliation:
Thomas Jefferson University, Philadelphia
Stephen M. Stahl
Affiliation:
University of California, San Diego
Get access

Summary

THERAPEUTICS

Brands

• Nymalize, Nimotop

Generic?

• Yes

Class

• Calcium channel blocker

Commonly Prescribed for

(FDA approved in bold)

Reduce the incidence and severity of ischemic deficits in adult patients with subarachnoid hemorrhage (SAH) from ruptured intracranial berry aneurysms regardless of their post-ictus neurological condition (i.e., Hunt and Hess Grades I–V)

• Hypertension

• Traumatic brain injury

• Reversible cerebral vasoconstrictive syndromes (RCVS)

How the Drug Works

• Cardiac and vascular smooth muscle contraction depends on movement of calcium through L-type calcium channels, which is inhibited by nimodipine. In animals, nimodipine has a greater effect on cerebral arteries compared with other calcium channel blockers, probably because it is more lipophilic. There is no angiographic evidence that this is correct

How Long Until It Works

• Within hours for both SAH vasospasm and hypertension

If It Works

• Prevents delayed ischemic complications after SAH caused by vasospasm, improves recovery time, and reduces disability

• Typically used for 3 weeks

If It Doesn't Work

• Continue supportive care

Best Augmenting Combos for Partial Response or Treatment-Resistance

• Treatment of SAH should take place in a medical center with experience and 24-hour physician availability

• Occlude the aneurysm in SAH by surgery or coiling

• Do not treat hypertension aggressively

• Normovolemia is preferred

• Treat hyperglycemia and use measures to avoid deep vein thrombosis

Tests

• Monitor blood pressure and heart rate

ADVERSE EFFECTS (AEs)

How the Drug Causes AEs

• Direct effects of L-type calcium receptor antagonism on cardiac and smooth muscle

Notable AEs

• Hypotension, bradycardia

• Flushing, headache, constipation, nausea, myalgia, edema

Life-Threatening or Dangerous AEs

• Rare elevation of hepatic transaminases or thrombocytopenia

• May slow AV conduction or worsen symptoms of heart failure

Weight Gain

• Unusual

Sedation

• Unusual

What to Do About AEs

• Complications of SAH are more serious than significant AEs due to nimodipine. Continue or lower dose

Type
Chapter
Information
Essential Neuropharmacology
The Prescriber's Guide
, pp. 363 - 365
Publisher: Cambridge University Press
Print publication year: 2015

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

  • Nimodipine
  • Stephen D. Silberstein, Thomas Jefferson University, Philadelphia, Michael J. Marmura, Thomas Jefferson University, Philadelphia, Hsiangkuo Yuan, Thomas Jefferson University, Philadelphia
  • Edited in consultation with Stephen M. Stahl, University of California, San Diego
  • Book: Essential Neuropharmacology
  • Online publication: 06 October 2020
  • Chapter DOI: https://doi.org/10.1017/9781316161753.100
Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

  • Nimodipine
  • Stephen D. Silberstein, Thomas Jefferson University, Philadelphia, Michael J. Marmura, Thomas Jefferson University, Philadelphia, Hsiangkuo Yuan, Thomas Jefferson University, Philadelphia
  • Edited in consultation with Stephen M. Stahl, University of California, San Diego
  • Book: Essential Neuropharmacology
  • Online publication: 06 October 2020
  • Chapter DOI: https://doi.org/10.1017/9781316161753.100
Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

  • Nimodipine
  • Stephen D. Silberstein, Thomas Jefferson University, Philadelphia, Michael J. Marmura, Thomas Jefferson University, Philadelphia, Hsiangkuo Yuan, Thomas Jefferson University, Philadelphia
  • Edited in consultation with Stephen M. Stahl, University of California, San Diego
  • Book: Essential Neuropharmacology
  • Online publication: 06 October 2020
  • Chapter DOI: https://doi.org/10.1017/9781316161753.100
Available formats
×